Bank of America’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $104M | Buy |
619,352
+35,525
| +6% | +$5.27M | 0.01% | 1158 |
|
|
2026
Q1 | $76.9M | Buy |
583,827
+55,723
| +11% | +$7.39M | 0.01% | 1308 |
|
|
2025
Q4 | $74.9M | Sell |
528,104
-176,150
| -25% | -$25.5M | 0.01% | 1289 |
|
|
2025
Q3 | $98.9M | Buy |
704,254
+51,243
| +8% | +$6.94M | 0.01% | 1211 |
|
|
2025
Q2 | $82.1M | Buy |
653,011
+91,942
| +16% | +$10.5M | 0.01% | 1300 |
|
|
2025
Q1 | $62.1M | Buy |
561,069
+77,035
| +16% | +$9.76M | 0.01% | 1407 |
|
|
2024
Q4 | $66.1M | Sell |
484,034
-139,554
| -22% | -$17.3M | 0.01% | 1293 |
|
|
2024
Q3 | $71.8M | Buy |
623,588
+4,657
| +0.8% | +$638K | 0.01% | 1287 |
|
|
2024
Q2 | $85.2M | Buy |
618,931
+52,218
| +9% | +$7.16M | 0.01% | 1104 |
|
|
2024
Q1 | $78.2M | Buy |
566,713
+93,734
| +20% | +$12.8M | 0.01% | 1180 |
|
|
2023
Q4 | $62.3M | Sell |
472,979
-86,792
| -16% | -$9.99M | 0.01% | 1208 |
|
|
2023
Q3 | $63M | Buy |
559,771
+80,033
| +17% | +$8.43M | 0.01% | 1151 |
|
|
2023
Q2 | $45.2M | Sell |
479,738
-69,757
| -13% | -$6.82M | ﹤0.01% | 1384 |
|
|
2023
Q1 | $55.6M | Sell |
549,495
-49,851
| -8% | -$5.19M | 0.01% | 1290 |
|
|
2022
Q4 | $71.6M | Sell |
599,346
-111,085
| -16% | -$13M | 0.01% | 1079 |
|
|
2022
Q3 | $75.5M | Buy |
710,431
+126,109
| +22% | +$12.8M | 0.01% | 992 |
|
|
2022
Q2 | $57M | Sell |
584,322
-11,486
| -2% | -$1.06M | 0.01% | 1194 |
|
|
2022
Q1 | $55.9M | Buy |
595,808
+89,721
| +18% | +$7.6M | 0.01% | 1287 |
|
|
2021
Q4 | $43.1M | Sell |
506,087
-84,478
| -14% | -$7.77M | ﹤0.01% | 1514 |
|
|
2021
Q3 | $56.6M | Buy |
590,565
+10,278
| +2% | +$971K | 0.01% | 1274 |
|
|
2021
Q2 | $56.5M | Sell |
580,287
-149,913
| -21% | -$14.4M | 0.01% | 1291 |
|
|
2021
Q1 | $71M | Buy |
730,200
+102,071
| +16% | +$10.7M | 0.01% | 1059 |
|
|
2020
Q4 | $60.2M | Buy |
628,129
+204,046
| +48% | +$19.7M | 0.01% | 1065 |
|
|
2020
Q3 | $40.8M | Sell |
424,083
-72,654
| -15% | -$8.4M | 0.01% | 1194 |
|
|
2020
Q2 | $60.6M | Buy |
496,737
+122,236
| +33% | +$13.5M | 0.01% | 927 |
|
|
2020
Q1 | $32.4M | Sell |
374,501
-38,084
| -9% | -$3.73M | 0.01% | 1191 |
|
|
2019
Q4 | $44.3M | Sell |
412,585
-8,346
| -2% | -$874K | 0.01% | 1262 |
|
|
2019
Q3 | $37.9M | Sell |
420,931
-48,356
| -10% | -$4.52M | 0.01% | 1318 |
|
|
2019
Q2 | $39.6M | Sell |
469,287
-46,440
| -9% | -$3.81M | 0.01% | 1302 |
|
|
2019
Q1 | $45.4M | Buy |
515,727
+109,807
| +27% | +$9.18M | 0.01% | 1167 |
|
|
2018
Q4 | $29M | Sell |
405,920
-200,698
| -33% | -$19.2M | 0.01% | 1389 |
|
|
2018
Q3 | $74.6M | Sell |
606,618
-57,176
| -9% | -$6.49M | 0.01% | 859 |
|
|
2018
Q2 | $65.2M | Sell |
663,794
-12,353
| -2% | -$1.11M | 0.01% | 923 |
|
|
2018
Q1 | $56.1M | Buy |
676,147
+85,272
| +14% | +$7.2M | 0.01% | 983 |
|
|
2017
Q4 | $45.8M | Buy |
590,875
+41,664
| +8% | +$2.84M | 0.01% | 1151 |
|
|
2017
Q3 | $33.7M | Buy |
549,211
+72,341
| +15% | +$3.82M | 0.01% | 1459 |
|
|
2017
Q2 | $21.9M | Buy |
476,870
+56,412
| +13% | +$2.74M | ﹤0.01% | 1645 |
|
|
2017
Q1 | $18.2M | Buy |
420,458
+178,326
| +74% | +$7.64M | ﹤0.01% | 1836 |
|
|
2016
Q4 | $9.37M | Buy |
242,132
+16,035
| +7% | +$726K | ﹤0.01% | 2374 |
|
|
2016
Q3 | $11.4M | Buy |
226,097
+120,053
| +113% | +$5.98M | ﹤0.01% | 2113 |
|
|
2016
Q2 | $4.82M | Buy |
106,044
+30,046
| +40% | +$1.38M | ﹤0.01% | 2823 |
|
|
2016
Q1 | $3.01M | Sell |
75,998
-26,888
| -26% | -$1.07M | ﹤0.01% | 3221 |
|
|
2015
Q4 | $5.82M | Buy |
102,886
+14,850
| +17% | +$755K | ﹤0.01% | 2789 |
|
|
2015
Q3 | $3.5M | Buy |
88,036
+64,010
| +266% | +$3.09M | ﹤0.01% | 3227 |
|
|
2015
Q2 | $1.15M | Buy |
24,026
+18,134
| +308% | +$769K | ﹤0.01% | 3985 |
|
|
2015
Q1 | $234K | Sell |
5,892
-2,829
| -32% | -$101K | ﹤0.01% | 4832 |
|
|
2014
Q4 | $195K | Sell |
8,721
-1,948
| -18% | -$36.9K | ﹤0.01% | 5386 |
|
|
2014
Q3 | $167K | Sell |
10,669
-40,304
| -79% | -$602K | ﹤0.01% | 5551 |
|
|
2014
Q2 | $757K | Buy |
50,973
+11,336
| +29% | +$160K | ﹤0.01% | 4230 |
|
|
2014
Q1 | $638K | Buy |
39,637
+20,467
| +107% | +$350K | ﹤0.01% | 4369 |
|
|
2013
Q4 | $179K | Buy |
19,170
+8,470
| +79% | +$82.7K | ﹤0.01% | 5690 |
|
|
2013
Q3 | $121K | Sell |
10,700
-17,186
| -62% | -$236K | ﹤0.01% | 5823 |
|
|
2013
Q2 | $373K | Buy |
+27,886
| New | +$343K | ﹤0.01% | 5029 |
|
Other funds holding NBIX
Bank of America's NBIX Position: Q2 2026 in Review
Bank of America increased its Neurocrine Biosciences (NBIX) stake by 6.1% in Q2 2026, buying an estimated $5.27M and bringing the position to 619,352 shares worth $104M. The position accounts for 0.01% of the portfolio, ranked #1158.
Bank of America first reported a position in NBIX in Q2 2013 and has held it in 53 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Bank of America held 619,352 shares of Neurocrine Biosciences worth $104M as of Q2 2026.
- Bank of America bought 35,525 Neurocrine Biosciences shares in Q2 2026, an estimated $5.27M.
- Neurocrine Biosciences made up 0.01% of Bank of America's portfolio in Q2 2026, its #1158 holding.
- Bank of America first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 53 quarters since.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.